Stephanie van Hoppe

94 Chapter 4 Supplemental Figure 5 - Kidney and spleen concentration ( A, D ), tissue-to-plasma ratio ( B, E ) and relative tissue accumulation ( C, F ) of ibrutinib in female WT, Abcb1a/1b -/- , Abcg2 -/- and Abcb1a/1b;Abcg2 -/- mice 1 h after oral administration of 10 mg/kg ibrutinib. *, P < 0.05; **, P < 0.01 compared to WT mice. Data are given as mean ± SD. n = 5−6 mice per group. Suppl mental Figure 5. Kidney and spleen concentration ( A, D ), tissue-to-plasma ratio ( B, E ) and relative tissue accumulation ( C, F ) of ibrutinib in female WT, Abcb1a/1b -/- , Abcg2 -/- and Abcb1a/1b;Abcg2 -/- mice 1 h after oral administration of 10 mg/kg ibrutinib. *, P < 0.05; **, P < 0.01 compared to WT mice. Data are given as mean ± SD. n = 5−6 mice per group. WT Abcg2 -/- Abcb1a/1b -/- Abcb1a/1b;Abcg2 -/- 0 100 200 300 Ibrutinib kidney concentration (ng/g) WT Abcg2 -/- Abcb1a/1b -/- Abcb1a/1b;Abcg2 -/- 0 100 200 300 Ibrutinib spleen concentration (ng/g) WT Abcg2 -/- Abcb1a/1b -/- Abcb1a/1b;Abcg2 -/- 0 1 2 3 4 Ibrutinib kidney to plasma ratio WT Abcg2 -/- Abcb1a/1b -/- Abcb1a/1b;Abcg2 -/- 0.0 0.5 1.0 1.5 2.0 Ibrutinib spleen to plasma ratio WT Abcg2 -/- Abcb1a/1b -/- Abcb1a/1b;Abcg2 -/- 0.0 0.5 1.0 1.5 Ibrutinib kidney accumulation (h -1 ) WT Abcg2 -/- Abcb1a/1b -/- Abcb1a/1b;Abcg2 -/- 0.0 0.2 0.4 0.6 0.8 Ibrtuinib spleen accumulation (h -1 ) A B C D E F 1-hour experiment * **